(Total Views: 429)
Posted On: 03/03/2020 7:54:45 AM
Post# of 153974
Ohm,
Thanks for your input in pointing out (rightly) that Leronlimab would not be affective in a HV-like fashion (antagonist) in the Coronavirus case.
I also fell for this paper and though that the doors were opened to HIV drugs due to the 4 four inserts aligned with short segments of HIV.
As you suggested then, and Dr. Patterson confirmed latter, the MOA of Leronlimab is in helping to control the Acute Respiratory Distress Syndrome (ARDS) is different:
Quoting Dr. Patterson:
Thanks for your input in pointing out (rightly) that Leronlimab would not be affective in a HV-like fashion (antagonist) in the Coronavirus case.
I also fell for this paper and though that the doors were opened to HIV drugs due to the 4 four inserts aligned with short segments of HIV.
As you suggested then, and Dr. Patterson confirmed latter, the MOA of Leronlimab is in helping to control the Acute Respiratory Distress Syndrome (ARDS) is different:
Quoting Dr. Patterson:
Quote:
Leronlimab has both the potential to enhance the cellular immune response by suppressing Treg cells that, in turn, inhibit the anti-viral T-cell responses and the potential to repolarize macrophage activity. Lung (alveolar) macrophages in coronavirus infections have been implicated as a contributing factor to significant morbidity and mortality of the infectious disease. Leronlimab could potentially synergize with other retroviral therapies that are currently being used for the potential treatment of 2019-nCoV.
(0)
(0)
